Asia Pacific Small Molecule Contract Development and Manufacturing Organization (CDMO) Market 2021-2031 by Product Type (API, FDF), Service Type (Preclinical, Clinical, Commercial), Customer Type (Pharmaceutical Firms, Biotechnology Firms), Therapeutic Area (Infectious Diseases, Oncology, Ophthalmology, Cardiovascular Disorders, Central Nervous System, Respiratory Disorders, Metabolic Diseases), and Country: Trend Forecast and Growth Opportunity

Asia Pacific small molecule contract development and manufacturing organization (CDMO) market will grow by 8.3% annually with a total addressable market cap of $234,210.0 million over 2022-2031, driven by the increasing demand for small molecule medicines and therapies, a rising demand for cost control in drug development, the increasing incidence of disease, and rising healthcare expenditures.
Highlighted with 31 tables and 51 figures, this 110-page report "Asia Pacific Small Molecule Contract Development and Manufacturing Organization (CDMO) Market 2021-2031 by Product Type (API, FDF), Service Type (Preclinical, Clinical, Commercial), Customer Type (Pharmaceutical Firms, Biotechnology Firms), Therapeutic Area (Infectious Diseases, Oncology, Ophthalmology, Cardiovascular Disorders, Central Nervous System, Respiratory Disorders, Metabolic Diseases), and Country: Trend Forecast and Growth Opportunity" is based on a comprehensive research of the entire Asia Pacific small molecule contract development and manufacturing organization (CDMO) market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2019-2021 and provides forecast from 2022 till 2031 with 2021 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter's Fiver Forces
The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19 and Russia-Ukraine conflict. The balanced (most likely) projection is used to quantify Asia Pacific small molecule contract development and manufacturing organization (CDMO) market in every aspect of the classification from perspectives of Product Type, Service Type, Customer Type, Therapeutic Area, and Country.

Based on Product Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
• Active Pharmaceutical Ingredients (API)
o Branded Drugs
o Generic Drugs
• Finished Dosage Formulations (FDF)
o Oral Solid Drugs
o Injectable Drugs
o Semi-solid or Liquid Drugs
o Other FDFs

Based on Service Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
• Preclinical Use
• Clinical Use
o Phase I
o Phase II
o Phase III
o Phase IV
• Commercial Use

By Customer Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
• Pharmaceutical Firms
• Biotechnology Firms

By Therapeutic Area, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
• Infectious Diseases
• Oncology
• Ophthalmology
• Cardiovascular Disorders
• Central Nervous System
• Respiratory Disorders
• Metabolic Diseases
• Other Therapeutic Areas

Geographically, the following national/local markets are fully investigated:
• Japan
• China
• South Korea
• Australia
• India
• Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)
For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2021-2031. The breakdown of national markets by Product Type, Service Type and Therapeutic Area over the forecast years are also included.

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Selected Key Players:
Boehringer Ingelheim
Cambrex Corporation
Catalent
Cipla
Covance Inc.
Lonza Group Ltd.
Medley Pharmaceuticals
NatcoPharma
Patheon (Thermo Fisher Scientific, Inc.)
Piramal Pharma Solutions
RedHillBiopharma
Siegfried Holding AG
STA Pharmaceutical
Sun Pharmaceutical
Teva
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

1 Introduction 7
1.1 Industry Definition and Research Scope 7
1.1.1 Industry Definition 7
1.1.2 Research Scope 8
1.2 Research Methodology 11
1.2.1 Overview of Market Research Methodology 11
1.2.2 Market Assumption 12
1.2.3 Secondary Data 12
1.2.4 Primary Data 12
1.2.5 Data Filtration and Model Design 13
1.2.6 Market Size/Share Estimation 14
1.2.7 Research Limitations 15
1.3 Executive Summary 16
2 Market Overview and Dynamics 19
2.1 Market Size and Forecast 19
2.1.1 Impact of COVID-19 on World Economy 20
2.1.2 Impact of COVID-19 on the Market 22
2.2 Major Growth Drivers 24
2.3 Market Restraints and Challenges 28
2.4 Emerging Opportunities and Market Trends 31
2.5 Porter's Fiver Forces Analysis 35
3 Segmentation of Asia Pacific Market by Product Type 39
3.1 Market Overview by Product Type 39
3.2 Active Pharmaceutical Ingredients (API) 41
3.2.1 Branded Drugs 42
3.2.2 Generic Drugs 43
3.3 Finished Dosage Formulations (FDF) 44
3.3.1 Oral Solid Drugs 46
3.3.2 Injectable Drugs 47
3.3.3 Semi-solid or Liquid Drugs 48
3.3.4 Other FDFs 49
4 Segmentation of Asia Pacific Market by Service Type 50
4.1 Market Overview by Service Type 50
4.2 Preclinical Use 52
4.3 Clinical Use 53
4.3.1 Phase I 55
4.3.2 Phase II 56
4.3.3 Phase III 57
4.3.4 Phase IV 58
4.4 Commercial Use 59
5 Segmentation of Asia Pacific Market by Customer Type 60
5.1 Market Overview by Customer Type 60
5.2 Pharmaceutical Firms 62
5.3 Biotechnology Firms 63
6 Segmentation of Asia Pacific Market by Therapeutic Area 64
6.1 Market Overview by Therapeutic Area 64
6.2 Infectious Diseases 66
6.3 Oncology 67
6.4 Ophthalmology 68
6.5 Cardiovascular Disorders 69
6.6 Central Nervous System 70
6.7 Respiratory Disorders 71
6.8 Metabolic Diseases 72
6.9 Other Therapeutic Areas 73
7 Asia-Pacific Market 2021-2031 by Country 74
7.1 Overview of Asia-Pacific Market 74
7.2 Japan 77
7.3 China 80
7.4 Australia 82
7.5 India 84
7.6 South Korea 86
7.7 Rest of APAC Region 88
8 Competitive Landscape 90
8.1 Overview of Key Vendors 90
8.2 New Product Launch, Partnership, Investment, and M&A 93
8.3 Company Profiles 94
Boehringer Ingelheim 94
Cambrex Corporation 96
Catalent 97
Cipla 98
Covance Inc. 99
Lonza Group Ltd. 100
Medley Pharmaceuticals 101
NatcoPharma 102
Patheon (Thermo Fisher Scientific, Inc.) 103
Piramal Pharma Solutions 104
RedHillBiopharma 105
Siegfried Holding AG 106
STA Pharmaceutical 107
Sun Pharmaceutical 108
Teva 109
RELATED REPORTS 110

Choose License Type

Happy To Assist You

Contact Images

We will be happy to help you find what you need. Please call us or write to us:

Frequently Asked Questions

This report incorporates the analysis of factors that augments the market growth. Report presents competitive landscape of the global market. This also provides the scope of different segments and applications that can potentially influence the market in the future. The analysis is based on current market trends and historic growth data. It includes detailed market segmentation, regional analysis, and competitive landscape of the industry.
The report efficiently evaluates the current market size and provides industry forecast. The market was valued at xxx Million US$ in 2019, and is expected to grow at a CAGR of xx% during the period 2020-2027.
The report efficiently evaluates the current market size and provides forecast for the industry in terms of Value (US$ Mn) and Volume (Thousands Units).
Market is segmented by:
  • Product Types
  • Drug Class
  • Indication
  • Applications
  • Services Types
  • End-users
  • Distribution channel
  • Regions
The report share key insights on the following:
  • Current market size
  • Market forecast
  • Market opportunities
  • Key drivers
  • Restraints
  • Pipeline Analysis
  • Incidence Rate
  • Epidemiology Analysis
  • Prevalence rate
  • Regulatory scenario
  • Industry trend
  • Pestle Analysis
  • Porter’s Analysis
  • New product approvals/launch
  • Promotion and marketing initiatives
  • Pricing analysis
  • Export-import analysis
  • Trade analysis
  • Competitive landscape
It helps the businesses in making investments decisions.
Customization helps the organization to gain insight on specific segments and regions of interest. Thus, WMR offers tailored report information based on business requirement in order to take strategic calls.
Contact us

mapicon
Sales Office (U.S.):
Worldwide Market Reports, 533 Airport Boulevard, Suite 400, Burlingame, CA 94010, United States

mapicon+1-415-871-0703

mapicon
Asia Pacific Intelligence Center (India):
Worldwide Market Reports, 403, 4th Floor, Bremen Business Center, Aundh, Pune, Maharashtra 411007, India.

Newsletter

Want us to send you latest updates of the current trends, insights, and more, signup to our newsletter (for alerts, special offers, and discounts).


Secure Payment By:
paymenticon

This website is secured Origin CA certificate on the server, Comodo, Firewall and Verified Sitelock Malware Protection

secureimg

© 2023 Worldwide Market Reports. All Rights Reserved